Medicine–Food Homology Bioactives for Polyendocrine Metabolic Ovarian Syndrome: Multi-Target Mechanisms and Functional Food Translation
4 affiliations
- 1College of Pharmaceutical Science, Dali University, Dali 671003, China
- 2Key Laboratory of Traditional Chinese Medicine for Prevention and Treatment of Neuropsychiatric Diseases, Yunnan University of Chinese Medicine, Kunming 650500, China
- 3The First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming 650500, China
- 4Yunnan Academy of Agricultural Engineering, Kunming 650215, China
Abstract
Polyendocrine Metabolic Ovarian Syndrome (PMOS) is characterized by insulin resistance, hyperandrogenism, chronic inflammation, and oxidative stress, with a global prevalence of 10–13% and limited current drug treatments. Medicine–Food Homology (MFH) materials are rich in bioactive compounds such as polyphenols, flavonoids, and polysaccharides, offering potential multi-target nutritional interventions for PMOS, although safety data remain limited mainly to single compounds. A systematic search of the literature was conducted across PubMed/MEDLINE, Web of Science CNKI, and Wanfang Data, spanning from database inception to August 2026, utilizing predefined search terms and inclusion/exclusion criteria. This review summarizes research on MFH-derived bioactive compounds in PMOS, covering active component identification, network pharmacology-based target prediction, key signaling pathways (PI3K/AKT, AMPK, NF-κB, Nrf2/HO-1), and formulation strategies including green extraction, nano-encapsulation, and controlled release. It further discusses functional food development from five perspectives: meal replacement powders, functional teas, fermented beverages, dietary supplements, and compound formulations. Key bottlenecks hindering commercialization are analyzed, including insufficient high-quality clinical evidence, unclear dose–response relationships, and limited long-term stability data. Future directions are proposed, such as organoids, organ-on-a-chip, AI-driven formulation optimization, and international multicenter trials. In summary, MFH bioactive compounds show potential as multi-target interventions for PMOS; however, most mechanistic evidence comes from non-PMOS metabolic models, and direct PMOS-specific evidence is limited. Their translation from empirical use to evidence-based intervention requires PMOS-specific preclinical validation, randomized controlled trials, safety assessments, bioavailability evaluation, and standardized product validation, alongside collaborative efforts across research paradigms, technology development, and industrial translation.
Related
- Ovarian fibrosis in polyendocrine metabolic ovarian syndrome: emerging mechanisms and therapeutic implications
- Phytosomal Delivery of Natural Bioactives: Advancing Bioavailability, Targeted Drug Delivery, and Clinical Translation.
- Edible Mushroom Polysaccharides as Functional Food Ingredients for Metabolic Health: Preparation, Techno-Functional Behavior, and Requirements for Translation.
- Real‐World Metabolic Improvements in Women With and Without Polyendocrine Metabolic Syndrome via a Multidisciplinary Telehealth Care Platform
- Polyendocrine metabolic ovarian syndrome in adolescents.
BibTeX
@article{lv2026medicinefood,
title = {{Medicine–Food Homology Bioactives for Polyendocrine Metabolic Ovarian Syndrome: Multi-Target Mechanisms and Functional Food Translation}},
author = {Xiaoman Lv and Wenjuan Long and Zhongyang Hu and Mingqin Shi and Xinyao Li and Yujun Feng and Jiarong Du and Zhicheng Yang and Fang Peng and Liwei Xing and Dongdong Qin},
journal = {Molecules},
year = {2026},
month = oct,
doi = {10.3390/molecules31203633},
url = {https://www.mdpi.com/1420-3049/31/20/3633},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Medicine–Food Homology Bioactives for Polyendocrine Metabolic Ovarian Syndrome: Multi-Target Mechanisms and Functional Food Translation
AU - Xiaoman Lv
AU - Wenjuan Long
AU - Zhongyang Hu
AU - Mingqin Shi
AU - Xinyao Li
AU - Yujun Feng
AU - Jiarong Du
AU - Zhicheng Yang
AU - Fang Peng
AU - Liwei Xing
AU - Dongdong Qin
PY - 2026
DA - 2026/10/01
JO - Molecules
DO - 10.3390/molecules31203633
UR - https://www.mdpi.com/1420-3049/31/20/3633
AB - Polyendocrine Metabolic Ovarian Syndrome (PMOS) is characterized by insulin resistance, hyperandrogenism, chronic inflammation, and oxidative stress, with a global prevalence of 10–13% and limited current drug treatments. Medicine–Food Homology (MFH) materials are rich in bioactive compounds such as polyphenols, flavonoids, and polysaccharides, offering potential multi-target nutritional interventions for PMOS, although safety data remain limited mainly to single compounds. A systematic search of the literature was conducted across PubMed/MEDLINE, Web of Science CNKI, and Wanfang Data, spanning from database inception to August 2026, utilizing predefined search terms and inclusion/exclusion criteria. This review summarizes research on MFH-derived bioactive compounds in PMOS, covering active component identification, network pharmacology-based target prediction, key signaling pathways (PI3K/AKT, AMPK, NF-κB, Nrf2/HO-1), and formulation strategies including green extraction, nano-encapsulation, and controlled release. It further discusses functional food development from five perspectives: meal replacement powders, functional teas, fermented beverages, dietary supplements, and compound formulations. Key bottlenecks hindering commercialization are analyzed, including insufficient high-quality clinical evidence, unclear dose–response relationships, and limited long-term stability data. Future directions are proposed, such as organoids, organ-on-a-chip, AI-driven formulation optimization, and international multicenter trials. In summary, MFH bioactive compounds show potential as multi-target interventions for PMOS; however, most mechanistic evidence comes from non-PMOS metabolic models, and direct PMOS-specific evidence is limited. Their translation from empirical use to evidence-based intervention requires PMOS-specific preclinical validation, randomized controlled trials, safety assessments, bioavailability evaluation, and standardized product validation, alongside collaborative efforts across research paradigms, technology development, and industrial translation.
SN - 1420-3049
ER -